A typical ipamorelin dose is 200 to 300 micrograms (mcg) per injection, given subcutaneously once daily. Most protocols call for five days on and two days off each week, and cycles generally run about three months before a one-month break. That said, ipamorelin is not FDA-approved, and dosing guidance comes from compounding clinics and limited clinical research rather than standardized prescribing information.
How Ipamorelin Works
Ipamorelin is a synthetic peptide that mimics ghrelin, the hormone your body uses to signal growth hormone release from the pituitary gland. It binds to ghrelin receptors and triggers a pulse of growth hormone. What makes it notable among growth hormone-releasing peptides is its selectivity: a 1998 study published in the European Journal of Endocrinology described it as the first growth hormone secretagogue that stimulates growth hormone without meaningfully raising cortisol or prolactin, two hormones that other peptides in this class tend to elevate as unwanted side effects.
After a subcutaneous injection, growth hormone levels peak at roughly 40 minutes and then decline in a pattern that looks like a natural growth hormone pulse. Clinical pharmacology modeling in human volunteers confirmed this single-peak response across a range of doses, with growth hormone returning to baseline levels relatively quickly. This pulsatile pattern is part of why ipamorelin appeals to people looking to support growth hormone without the flat, sustained elevation that comes from injecting growth hormone directly.
Common Dosing Protocols
Compounding clinics typically prescribe ipamorelin at one of two dose levels:
- 200 mcg per day: Often the starting dose. With a standard 2 mg/mL vial, this works out to 0.1 mL per injection.
- 300 mcg per day: A step up for people who tolerate the lower dose well. This is 0.15 mL from the same concentration vial.
Both protocols follow a five-days-on, two-days-off weekly schedule. The off days help prevent your pituitary gland from becoming desensitized to the peptide over time. Some clinicians prescribe ipamorelin alongside another peptide called CJC-1295 (without DAC), which extends the growth hormone pulse. When combined, the dosing volume per injection is sometimes lower (0.05 to 0.1 mL of each peptide), so the specific amounts depend on what your prescriber has compounded in the vial.
When and How to Inject
Timing matters more than most people expect. Ipamorelin works best on an empty stomach, at least two to three hours after your last meal. Food, especially carbohydrates and fats, blunts the growth hormone response by raising insulin, which directly competes with growth hormone release.
The most common timing is between 6 and 8 p.m. or right before bed. Evening dosing takes advantage of your body’s natural growth hormone cycle, which peaks during deep sleep around 1 a.m. An injection in the early evening primes the pituitary so that the natural nighttime pulse is amplified rather than replaced. Some people inject in the morning on an empty stomach instead, but the evening protocol is more widely recommended.
Injections are subcutaneous, meaning just under the skin. The lower abdomen (rotating sides) is the most common site. Use a short insulin syringe, pinch a fold of skin, and inject at a 45-degree angle. Rotate injection sites to avoid tissue irritation.
Reconstitution and Storage
Ipamorelin typically arrives as a freeze-dried powder in a sealed vial. Before you can inject it, you need to mix it with bacteriostatic water. For a standard 5 mg vial, adding 3.0 mL of bacteriostatic water gives you a concentration of about 1.67 mg/mL (1,667 mcg/mL). Draw the water into a sterile syringe, inject it slowly down the inside wall of the vial, and gently swirl until the powder dissolves. Never shake the vial, as this can damage the peptide and cause it to clump.
Once reconstituted, store the vial in the refrigerator at 2 to 8°C (roughly 36 to 46°F). Peptide solutions degrade faster than dry powder, so label your vial with the date you mixed it and plan to use it within a few weeks. Unreconstituted vials last longer and can be stored in the freezer at minus 20°C for extended periods. Keep all vials away from bright light.
Cycle Length and Breaks
A standard ipamorelin cycle runs about three months on, followed by one month off. That gives you roughly three full cycles per year. The break periods serve a practical purpose: your pituitary gland’s ghrelin receptors can downregulate with continuous stimulation, meaning you’d need higher doses to get the same growth hormone response. A month off lets receptor sensitivity reset.
Some people notice the effects of ipamorelin (better sleep quality, improved recovery from exercise, changes in body composition) within the first few weeks, while for others the changes are more gradual and become noticeable around the six- to eight-week mark. The five-days-on, two-days-off weekly schedule serves as a mini-cycle within the larger three-month block, providing additional protection against desensitization.
Safety Considerations
Ipamorelin is not an FDA-approved drug. It has been available through compounding pharmacies under a prescriber’s order, but the FDA has flagged concerns about compounded peptide products in general. One significant concern is immunogenicity, meaning the body could develop an immune response to the peptide, particularly if the compounded product contains impurities or aggregated peptide fragments. Ipamorelin contains unnatural amino acids, which makes quality control during compounding more complex than with simpler peptides.
The FDA also noted that a published study found serious adverse events, including death, when ipamorelin was administered intravenously at high doses in a clinical setting focused on improving gut motility. That context (IV administration, hospitalized patients, different dosing) is very different from the subcutaneous protocols used in wellness settings, but it underscores that this peptide carries real pharmacological effects and real risks.
Common side effects reported at typical subcutaneous doses tend to be mild: injection site redness, headache, lightheadedness, and occasionally water retention or tingling in the hands and feet. These usually resolve as the body adjusts. More concerning would be persistent joint pain, significant swelling, or signs of elevated blood sugar, which could indicate excessive growth hormone stimulation.
Why Dose Precision Matters
Growth hormone secretagogues have a ceiling effect. Clinical research on related growth hormone-releasing peptides shows that beyond a certain dose, the pituitary simply cannot release more growth hormone per pulse. You hit a saturation point. Taking more ipamorelin than the 200 to 300 mcg range does not proportionally increase growth hormone output. It just increases your exposure to the peptide itself and any associated side effects. The pharmacokinetic modeling in human volunteers confirmed that growth hormone production follows a predictable curve with a defined maximum, regardless of how much peptide is circulating.
This is why the standard protocols stay in a relatively narrow dose range. More is not better with ipamorelin. Accuracy with your syringe measurements, consistent timing, and the discipline to take scheduled breaks will produce better long-term results than pushing the dose higher.